Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators

Molecular Carcinogenesis

Volumn 17, Issue 3, 1996, Pages 151-159

  Fuchs Young, Robin ^a,b   Howe, Susan ^c   Hale, Laura ^a   Miles, Rebecca ^a   Walker, Cheryl ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Selective estrogen receptor modulator; Uterine leiomyoma

Indexed keywords

ANTIESTROGEN; FULVESTRANT; RALOXIFENE; TAMOXIFEN;

ANIMAL CELL; CELL LINE; CONFERENCE PAPER; CONTROLLED STUDY; GROWTH INHIBITION; LEIOMYOMA; NONHUMAN; PRIORITY JOURNAL; RAT; UTERUS TUMOR;

ANIMALS; CELL DIVISION; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; LEIOMYOMA; PHENOTYPE; PIPERIDINES; RALOXIFENE; RATS; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

ANIMALIA;

EID: 0029952875     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199611)17:3<151::AID-MC7>3.0.CO;2-I     Document Type: Conference Paper

References (35)

1. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 94:435-438, 1990.
2. Bradham DD, Stovall TG, Thompson CD. Use of GnRH agonist before hysterectomy: A cost simulation. Obstet Gynecol 85:401- 406, 1995.
3. Christiansen J. The facts about fibroids. Postgrad Med 94:129- 137, 1993.
4. American College of Obstetricians and Gynecologists. Uterine leiomyomata. ACOG Technical Bulletin 192:1-9, 1994.
5. Rivlin ME, Patel RB, Hes LW, Hess DB, Meeks GR. Leuprolide acetate depot for the treatment of uterine leiomyomas: Changes in bone density, uterine volume and uterine vascular resistive index. J Reproductive Med 39:663-666, 1994.
6. Adamson GD. Treatment of uterine fibroids: Current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 156:746-751, 1992.
7. Van Der Ven LRM, Gloudemans T, Roholl PJM, et al. Growth advantage of human leiomyoma cells compared to normal smooth-muscle cells due to enhanced sensitivity toward insulin- like growth factor I. Int J Cancer 59:427-434, 1994.
8. Bowser AD, Haseman JK, Dixon D. Effects of transforming growth factor-alpha (TGF-α) on morphology and growth of uterine leiomyoma cells (LMC) in vitro. The Toxicologist 15:250, 1995.
9. Stewart E, Rein M, Freidman A, Zuchowski L, Nowak R. Glycoprotein hormones and their common a-subunit stimulate prolactin production by explant cultures of human leiomyoma and myometrium. Am J Obstet Gynecol 170:677-683, 1994.
10. Porter KB, Tsibris JCM, Nicosia SV, et al. Estrogen-induced guinea pig model for uterine leiomyomas: Do the ovaries protect? Biol Reprod 52:824-832, 1995.
11. Everitt J, Howe SR, Wolf D, Goldsworthy T, Walker C. Rodent model of reproductive tract leiomyomata: Clinical and pathologic features. Am J Pathol 146:1556-1567, 1995.
12. Kobayashi T, Hirayama Y, Kobayashi E, Kubo Y, Hino O. A germ- line insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat Genet 9:70-75, 1995.
13. Yeung RS, Xiao G-H, Jin F, Lee W-C, Testa JR, Knudson AG. Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc Natl Acad Sci USA 91:11413-11416, 1994.
14. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf D, Walker C. Rodent model of reproductive tract leiomyomata: Establishment and characterization of tumor-derived cell lines. Am J Pathol 146:1568-1579, 1995.
15. Howe SR, Gottardis MM, Everitt JI, Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology 136:4996-5003, 1995.
16. Black L, Sato M, Rowley E, et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63- 69, 1994.
17. Fuchs-Young R, Glasebrook AL, Short LL, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Proceedings of the New York Academy of Sciences 355-360, 1995.
18. Clemens J, Bennett D, Black L, Jones C. Effects of a new antiestrogen, keoxifene (LY156759), on growth of carcinogen- induced mammary tumors and on LH and prolactin levels. Life Sci 32:2869-2875, 1983.
19. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812- 815, 1988.
20. Thomas EJ, Walton PL, Thomas NM, Dowsett M. The effects of ICI 182,780, a pure antiestrogen, on the hypothalamic-pituitary- gonadal axis and on endometrial proliferation in pre-menopausal women. Hum Reprod 9:1191-1196, 1994.
21. Jones CD, Suarez T, Massey EH, Black LJ, Tinsley FC. Synthesis and anti-estrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl)4-(2-pyrroledenyl)ethoxy phenyl] methanone methanesulfonic acid salt. J Med Chem 22:962- 966, 1979.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987.
23. Hirata S, Osada T, Hirai M, Hagihara K, Kato J. Expression of estrogen receptor in the rat brain: Detection of its mRNA using reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 41:583-587, 1992.
24. Hagihara K, Hirata S, Osada T, Hirai M, Kato J. Expression of progesterone receptor in the neonatal rat brain cortex: Detection of its mRNA using reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 41:637-640, 1992.
25. Littlefield B, Gurpide E, Markeiwicz L, McKinley B, Hochberg R. A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in ishikawa cells. Endocrinology 127:2757-2762, 1990
26. May FE, Johnson MD, Wiseman LR, Wakeling AE, Kastner P, Westley BR. Regulation of progesterone receptor mRNA by oestradiol and antioestrogens in breast cancer cell lines. J Steroid Biochem Mol Biol 33:1035-1041, 1989.
27. Read LD, Snider CE, Miller JS, Greene GL, Katzenellenbogen BS. Ligand modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol 2:263-271, 1988.
28. Kraus WL, Katzenellenbogen BS. Regulation of progesterone receptor gene expression and growth in the rat uterus: Modulation of estrogen actions by progesterone and sex steroid hormone antagonists. Endocrinology 132:2371-2379, 1993.
29. Sundstrom SA, Komm BS, Xu Q, Boundy V, Lyttle R. The stimulation of uterine complement component C3 gene expression by antiestrogens. Endocrinology 126:1449-1456, 1990.
30. Das S, Tsukamura H, Paria B, Andrews G, Dey S. Differential expression of epidermal growth factor receptor (EGF-R) gene and regulation of EGF-R bioactivity by progesterone and estrogen in the adult mouse uterus. Endocrinology 134:971-981, 1994.
31. Gill PG, Vignon F, Bardon S, Derocq D, Rochefort H. Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells. Breast Cancer Res Treat 10:37-45, 1987.
32. Sutherland RL, Hall RE, Pang GY, Musgrove EA, Clarke CL. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 48:5084-5091, 1988.
33. Classen S, Possinger K, Pelka-Fleischer R, Wilmanns W. Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J Steroid Biochem Mol Biol 45:315-319, 1993.
34. L'Horset F, Blin C, Breur A, Thomasset M, Perret C. Estrogen- induced calbindin-D 9K gene expression in the rat uterus during the estrous cycle: Late antagonistic effects of progesterone. Endocrinology 132:489-495, 1993.
35. Ugwumadu AHN, Harding K. Uterine leiomyomata and endometrial proliferation in post-menopausal women treated with the antioestrogen tamoxifen. Biol Reprod 54:153-156, 1994.